Cargando…
Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome
Fibroblast growth factor-21 (FGF21) is elevated in patients with the metabolic syndrome. Although the exact underlying mechanisms remain ill-defined, chronic low-grade inflammation with increased Interleukin-(IL)-1β expression may be responsible. The aim of this study was to investigate effects of t...
Autores principales: | Ebrahimi, Fahim, Urwyler, Sandrine Andrea, Betz, Matthias Johannes, Christ, Emanuel Remigius, Schuetz, Philipp, Mueller, Beat, Donath, Marc Yves, Christ-Crain, Mirjam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041761/ https://www.ncbi.nlm.nih.gov/pubmed/33846498 http://dx.doi.org/10.1038/s41598-021-87207-w |
Ejemplares similares
-
Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial
por: Ebrahimi, Fahim, et al.
Publicado: (2019) -
SAT-066 Effect Of Interleukin-1-receptor Antagonist On Hemodynamics And Renin-angiotensin-aldosterone System In Obese Individuals
por: Urwyler, Sandrine, et al.
Publicado: (2019) -
The role of IL-1 in the regulation of copeptin in patients with metabolic syndrome
por: Popovic, Milica, et al.
Publicado: (2020) -
Association of adrenal insufficiency with patient-oriented health-care outcomes in adult medical inpatients
por: Ebrahimi, Fahim, et al.
Publicado: (2019) -
Risk of Adverse Clinical Outcomes in Hyponatremic Adult Patients Hospitalized for Acute Medical Conditions: A Population-Based Cohort Study
por: Kutz, Alexander, et al.
Publicado: (2020)